Cardiac Safety
Tryphaena
Patients n, (%)
FEC + HP x3
PHT x3
(n = 72)
FEC x3
PHT x3
(n = 75)
PHTC x6
(n = 76)
Symptomatic LVSD (grades ≥3)
0 (0.0)
2 (2.7)
0 (0.0)
LVSD (all grades)
4 (5.6)
3 (4.0)
2 (2.6)
LVEF decline ≥10% points and below 50%
4 (5.6)
4 (5.3)
3 (3.9)
LVSD, left ventricular systolic dysfunction; LVEF, left ventricular ejection fraction
FEC, 5-fluorouracil, epirubicin, cyclophosphamide; H, trastuzumab; P, pertuzumab; T, docetaxel; C, carboplatin
•
Low incidence of symptomatic and asymptomatic LVSD across all arms
Schneeweiss et al. Ann of Oncology 2013;
